Pa8ent Educa8on October 30th, 2019 NYU Non Tuberculous Mycobacteria Program Research Leopoldo N. Segal, MD, MS Division of Pulmonary and Critical Care Medicine DC 11/26/2019 NYU LANGONE NTM/Bronchiectasis Multidisciplinary Program ! ! !Program Co Directors Research Director DC 11/26/2019 NYU NTM/Bronchiectasis Program Adrienne Scott, MS Rosemary Schluger, RN Stephanie Lau, MD Amy Levinger, NP Ashley Drengler, BSc Emily Clementi, BSc Marla Sagatelian, BSc Danielle Harris !3 DC 11/26/2019NYU NTM/Bronchiectasis Program (Segal Lab) !4 DC 11/26/2019 NTM bronchiectasis: Increasing problem in US 5! Adjemian et al. Emerg Infect Dis. 2017 DC 11/26/2019 NTM bronchiectasis: Increasing problem Worldwide Japan South Korea !6 DC 11/26/2019100" 90" 80" 70" 60" 50" 40" 30" 20" 10" 0" FEV Cough and Sputum Production Structural Damage of the Lung Decline in LungFunction Diagnosis F/U and Prognosis Treatment DC 11/26/2019NYU Langone Lung & Airways Disease Registry !8 DC 11/26/2019Enrollment 600 497 500 400 325 300 200 158 110 100 6850 0 2014 2015 2016 2017 2018 2019 Exponential growth of enrollment !9 DC 11/26/2019 NYU Langone Lung & Airways Disease Registry Oregon Health and Science Mayo ClinicRochester University of Connecticut Columbia St. Luke's and Roosevelt National Jewish Medical Center Georgetown University University of Hospital Pennsylvania University of Illinois NIAID University University of North Carolina University of Texas University of Miami Mayo Clinic Florida !10 DC 11/26/2019 NYU Langone Lung & Airways Disease Registry Oregon Health and Science Mayo Clinic Rochester University of Connecticut Columbia NYU Langone Georgetown University Hospital University of Pennsylvania St. Luke's and Roosevelt National Jewish Medical Center University of Illinois NIAID University University of North Carolina University of Texas University of Miami Mayo Clinic Florida !11 DC 11/26/2019 Accomplishments: Registry Chronic Obstr Pulm Dis. 2019 Apr 9;6(2):145 153 DC 11/26/2019 Accomplishments: Clinical Trials A phase 3 randomized, double blind, placebo controlled study of liposomal amikacin for inhalation (Arikase®) in patients with resistant NTM lung disease lINS 212: A Randomized, Open Label, Multi center Study of Liposomal Amikacin for Inhalation (LAI) in Adult patients with NTM Lung Infections caused by MAC that are Refractory to Treatment Now Closed INS 312: An Open Label Safety Extension Study to a Multi center Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with NTM Lung Infections caused by MAC that are Refractory to Treatment DC 11/26/2019 Accomplishments: Clinical Trials Am J Respir Crit Care Med Vol 198, Iss 12, pp 1559 1569, Dec 15, 2018 DC 11/26/2019Double blind, placebo controlled, multi centre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non cystic fibrosis bronchiectasis chronically infected with P. aeruginosa Clinical Trials Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks in Subjects with Non C Fibrosis Bronchiectasis) A PILOT STUDY TO EVALUATE THE USE OF THE VEST® SYSTEM FOR TREATMENT OF NON CYSTIC FIBROSIS BRONCHIECTASIS PATIENTS IN THE HOME SETTING Multi center randomized pragmatic clinical trial comparing 2 versus 3 antibiotic therapy for pulmonary Mycobacterium avium complex disease Open DC 11/26/2019NTM disease is associated with micro aspiration !16 DC 11/26/2019Microaspiration ;H@MS¼ D¼ ?X]H;^¼ I8¼ =¡¼ªzp¼Nb­}p¼bl¼3lz¼\p~ep¡xp¡¼Hbe¸¡bª¼v¢¼7b¢l}­¥·¼Pp¨pb¡gz¼:b§ª¼DMQ;¼ Z@PMQH3Z¼ I8¼ u¼Bªp¡b¼Ipl}g}p¼ bl¼ ªzp¼8pb¡ªpª¼u¼L­¹\AHHB3I¼ P¼ >P3_¼ I8¼ gpb¡¼ Ipl}g}p¼ X}±p¡¨}ª¶¼ u¼ Tpµb¨¼ ?pbªz¼ 3H3L¼ F¼ NB;P7;¼ I8¼Qg~pgp¼7p«p¡¼bª¼8bb¨¼ bl¼ªzp¼8pb¡«pª¼u¼ Bªp¦b¼K~g~p¼Qª¼ Nb­¼?¨ªb¼8bb¨¼Upµb¨¼Sz}¨¼¨ª­l¶¼ ³b¨¼¨­¢ªpl¼ e¶¼ x¡bª¨¼u¡¼ªzp¼Qª¼Nb­¼ ?¨}ªb¼ =­mbª}¼ @g¼¼ bl¼ Y¼Q¼ N­eg¼?pbªz¼Qp¡±~gp¼>¡bª¼IMCPP#¼Pp ­p¨ª¨¼u¡¼¡p¡~ª¨¼¨z­l¼ep¼bll¡p¨¨pl¼ª¼8¡¼ 3b¼G¼N¡p¨pª¼bll¡p¨¨1¼Iª¼ Q~b~¼N¡up¨¨~b¼6­}l}x¼N}p¡gp¼ ¼ ?b¡¡¶¼ ?~p¨¼ 6­p±b¡l¼ ?R¼¼+¼\p¨ª¼F}e­¡¼3±p­p¼Q­ªp¼&¼I~³b­º9bb¨¼Spµb¨¼* ¼ Ib­¨g¡ª¼bggpªs¼3°­¨ª¼pp¼\}¨g¨~¼ ¼.¼ .)*¼»¼=p³¼ u¼ ªzp¼3p¡gb¼H­x¼ 3¨¨gbª}"%¼ 5£¼ 0( ¼ W|r¼5r£id¼E¯¤d¼w¼Jrojr¼ [¯r¼%¼ # ## # # ### ## "!# ` # Gleeson et al. Chest 1997 Radioactive 99mTc tracer !DC 11/26/2019 Swallow and NTM “Role of aerodigestive dysmotility on airway dysbiosis in NTM disease” • Subjects with Bronchiectasis undergoing swallow or upper GI evaluation • Swallow studies standardized to determine role of micro aspiration and GI motility • Paired evaluation of airway microbiota Ashwin Basavaraj, MD David Kamelhar, MD Matina Balou, PhD Abraham Khan, MD !18 DC 11/26/2019 NTM bronchiectasis: Increasing problem Worldwide MAC M. kansasii M. xenopi M. malmoense M. abscessus M. fortuitum !19 DC 11/26/2019NTM bronchiectasis: Increasing problem Worldwide !20 DC 11/26/2019The lower airways are like bars !21 DC 11/26/2019Microbe Isolation Microbial Product Identiﬁcation Culture Dependent Culture Independent 22 Microbiome: comprehensive characterization of the microbial communities !DC 11/26/2019Cough andSputum Production 1) NTM identiﬁcation? Diagnosis 2) Non NTM pathogens? 3) Patient susceptibility? DC 11/26/2019Accomplishments: Translational Research > 300 subjects with non invasive airway sampling > 100 subjects with invasive airway sampling DC 11/26/2019 Accomplishments: Translational Research Eur Respir J. 2018 Oct 25;52(4) DC 11/26/2019Pathogen Control Pathogen Susceptibility Increasing Anaerobes/SCFA IFN Ɣ production IFN Ɣ inhibitionCD4 FoxP3 IL 17A production IL 17A inhibition CD4 CD4 CD4 O HO FoxP1 CD4 O HO O HO CD8 CD4CD8 O FoxP1 OCD8 HO HO CD4 CD4 O NTM HO Antigen Segal et al. Cell Host & Microbe 2017 DC 11/26/2019The lower airways are like bars !27 DC 11/26/2019 Hypothesis • Bronchiectasis is a heterogenous disease • We hypothesize that in NTM related bronchiectasis lower airway dysbiosis aﬀects host immune phenotype and suscep=bility to pathogens DC 11/26/2019 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ●●● ●●●● ●●● ● ● ●● ● ● ● ●●● ●●●●●●● ●● ● ● ● ● ● ● ● ● ● ●●●●●● ● ● ● ● ● ● ● ● ● ●●●●●●●●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ●● ●●●● ● ●● ●●● ●● ● ●●● ●●● ●●●● ● ●● ● ●● ● ●●● ●●●● ●● ●OW ● ●●●●●●●●●● ● ● ●● ●●●● BKG●Sputum●● ●●●●● ●●●●●● ● ● ● ●●●●●● ● ●● Sup ● ●●● ●● ● ● ●●●●●●●● ●● ●● ●● ●●●●● ● ● ● ●● ●● ●● ●●●●●●● ●●●●●●●● ● ●● ● ●●●● BAL ● ● ● ●●●●● ● ●● ●●● ● ●● ●● ●●●● ● ● ● ●●●● ● ●●● ●● ● ● ●●● ●● ●●●● ● PC1: variance PC2: variance Growing cohort of patients with bronchiectasis with lowerairway samples Bronchiectasis Cohort n 89 Age 67[57 73] Gender 70() Spirometry FVC (% Predicted) 94[85 104]FEV1 (% Predicted) 88[77 100]FEV1/FVC 76[70 81] Culture Non Tuberculous Mycobacterium 22 () NTM + second pathogen 14() Haemophilus 6() Pseudomonas 5() Candida 4() Aspergillus 3() Streptococcus 3() Negative 28() Other 4() DC 11/26/2019Evalua7on of the Airway Microbiome In NTM Host Defense Disease Health !30 DC 11/26/2019Host Defense Disease Health Microbial environment: e.g. Biofilm Microbial Dynamics: • GERD • Impaired clearance !31 DC 11/26/2019A new challenge for Koch Postulate Host Factors Health Disease Biomarker) An#bio#cs) Pro$Bio'cs* Pre$Bio(cs+ Therapeu(c* LungMicrobiome Oral Microbiome Phage DC 11/26/2019 Be involved!! Ask us about research opportunities NYU Langone NTM/Bronchiectasis Program Funding Support: NIH/NIAID Chest Foundation We would like to acknowledge the generous support of donors to the NYU Langone NTM/bronchiectasis program: NTM Info & Research Helaine Lerner The Chelnik family in honor of Harriette and Martin Chelnik Beatrice Ifshin Barbara Goldstein Amster Wandler Family Karen Elliott House Leeam Lowin Sandra Pearl Lonuzzi Family Alan Manheimer Arthur Press Anonymous For more information about the program or opportunities for involvement, please contact Yodalis Moran (yodalis.Moran@nyulangone.org) or call 212 404 3538. 33! e mail: leopoldo.segal@nyumc.org DC 11/26/2019